![]() |
|
|
Vollum Institute for Advanced Biomedical Research (J.A.S., J.M.K., M.M.S., G.L.W.) and Departments of Medicine (T.P.S.) and Neurology (G.L.W.), Oregon Health Sciences University, Portland, Oregon 97201
| |
Summary |
|---|
|
|
|---|
The metabotropic glutamate receptor (mGluR) cDNAs were originally
cloned from rat, except for the mouse cDNA clone encoding mGluR8. Mouse
mGluR8 couples weakly to the inhibition of adenylate cyclase, thus
hindering the characterization of its pharmacological properties. We
isolated a rat mGluR8 cDNA that encodes a protein of 908 amino acids.
In situ hybridization revealed prominent mGluR8 mRNA
expression in olfactory bulb, pontine gray, lateral reticular nucleus
of the thalamus, and piriform cortex. Less abundant expression was
detected in cerebral cortex, hippocampus, cerebellum, and mammillary
body. Glutamate evoked pertussis toxin-sensitive potassium currents in
Xenopus laevis oocytes coexpressing mGluR8 and G
protein-coupled inwardly rectifying potassium channels. mGluR8 was also
activated by the group III-specific agonist
L-2-amino-4-phosphonobutyric acid;
(2(S),1
(S),2
(S)]-2-(carboxycyclopropyl)glycine,
which has been frequently used as a selective group II agonist; and the
nonselective agonist
(1(S),3(R)]-1-aminocyclopentane-1,3-dicarboxylic acid but not by the group I-specific agonist 3,5-dihydroxyphenylglycine or the group II-specific agonist
[2(S),1
(R),2
(R),3
(R)]-2-(2,3-dicarboxycyclopropyl)glycine. The agonist profile in order of potency was
[2(S),1
(S),2
(S)]-2-(carboxycyclopropyl)glycine
L-2-amino-4-phosphonobutyric acid > glutamate
[1(S),3(R)]-1-aminocyclopentane-1,3-dicarboxylic acid, with EC50 values of 0.63, 0.67, 2.5, and 47 µM, respectively. Both the group I/II-specific antagonist
(R,S)-
-methyl-4-carboxyphenylglycine and the group III-specific antagonist
-methyl-amino-phosphonobutyrate inhibited mGluR8. The
pharmacological profile of mGluR8 is distinct among mGluRs but closely
matches that of presynaptic inhibition in some central nervous system
pathways. Thus, cellular responses mediated by both group II and III
agonists may in some cases reflect activation of mGluR8 rather than
multiple mGluR subtypes.
| |
Introduction |
|---|
|
|
|---|
The role of mGluRs in synaptic transmission has become increasingly recognized, in large part due to their molecular characterization. Molecular cloning has identified a family of eight receptors that forms three subgroups based principally on their sequence identity but also on their agonist profile and primary signal transduction pathway (1, 2). Most neurons express multiple mGluR subtypes; thus, identification of the subtype responsible for particular in vivo responses has relied heavily on the distribution and pharmacological profile of cloned mGluRs. In some cases, such as mGluR2 in the accessory olfactory bulb (3) and mGluR6 in the retina (4), the distribution of mGluR RNA and protein is consistent with the responses evoked by group-specific agonists. However, in other cases, cellular responses to mGluR agonists do not match those of any of the cloned mGluRs. For example, responses evoked by mGluR agonists in spinal, cortical, and hippocampal neurons can display a mixed group II/III pharmacology. Specifically, MCPG antagonizes the L-AP4-induced depression of monosynaptic excitation in neonatal rat motoneurons and of forskolin-stimulated cAMP synthesis in guinea pig cerebrocortical slices (5, 6). MCPG also antagonizes the presynaptic inhibition mediated by L-AP4 and L-CCG-1 in guinea pig hippocampal neurons (7). This is surprising because L-AP4 selectively activates the cloned group III receptors (mGluRs 4 and 6-8), whereas MCPG is reported to selectively inhibit group I/II receptors (mGluRs 1-3 and 5) but not group III receptors (8-10).
In vitro pharmacological studies of the cloned group II/III mGluRs rely on assays of forskolin-stimulated cAMP inhibition. This assay has presented problems for the analysis of mGluR7 and mGluR8 because these mGluRs cause only partial cAMP inhibition (2, 9, 11). Coexpression of mGluRs with GIRKs in Xenopus laevis oocytes provides an electrophysiological assay that is particularly useful for group II/III mGluRs (12). We have used the GIRK assay to examine the pharmacological properties of rat mGluR8. As expected for a group III mGluR, mGluR8 was activated by L-AP4. However, the pharmacological profile is unique in that mGluR8 also was antagonized by MCPG, reportedly a group I/II antagonist (8), and was activated by low concentrations of L-CCG-1, which is frequently used as a group II-specific agonist (13).
| |
Experimental Procedures |
|---|
|
|
|---|
Materials. L-AP4, L-CCG-1, ACPD, DHPG, MAP4, and MCPG were purchased from Tocris Cookson (Bristol, UK). Glutamate and PTX were obtained from Sigma Chemical (St. Louis, MO). RNA transcription kits were obtained from Stratagene (La Jolla, CA), [32P]dCTP was obtained from Amersham (Arlington Heights, IL). DCG-IV was generously supplied by Dr. J. Conn (Emory University, Atlanta, GA) and Dr. H. Shinozaki (Tokyo Metropolitan Institute of Medical Science, Toyko, Japan). The pharmacological reagents were prepared as 50 or 100 mM stocks in water or equivalent NaOH and stored frozen. The cDNA clones encoding the rat GIRK1 (GIRK Kir3.1) and the rat CIR (cardiac inwardly rectifying potassium channel Kir3.4) were generously supplied by Dr. H. Lester (California Institute of Technology, Pasadena, CA) and Dr. J. Adelman (Vollum Institute, Oregon Health Sciences University, Portland, OR).
Isolation and sequence analysis of the rat mGluR8 cDNA.
The
cDNA encoding mGluR8 was isolated using previously described methods
(9). In brief, oligonucleotides were designed to amplify sequences
between transmembrane II and intracellular loop III of mGluRs using the
polymerase chain reaction. Three polymerase chain reaction products
(Olf 1, 2, and 8) were used as templates for the synthesis of
32P-labeled in vitro RNA transcripts that were
subsequently used to probe a rat olfactory bulb cDNA library
(Stratagene). Fourteen duplicate positive bacteriophage clones were
coinfected with helper phage into Escherichia coli for
analysis of their cDNA inserts into pBluescript SK(
). Southern blot
analysis identified three distinct groups of clones: Olf 8 labeled the
cDNA encoding rat mGluR8, whereas Olf 2 labeled mGluR7 (9, 11), and Olf
1 labeled mGluR5 (14). The cDNA was sequenced using an Applied
Biosystems 373 DNA automated sequencer (Norwalk, CT). A minimum of two
sequence reactions were performed for each region of the cDNA, and at
least three reactions were performed for regions that encoded amino acid sequence differences between the rat and mouse homologues. The
sequence information was managed and analyzed using the University of
Wisconsin Genetics Computer group software.
Expression of mGluR8 mRNA.
In situ hybridization
experiments were performed using adult female Sprague-Dawley rats that
were deeply anesthetized with pentobarbital and perfused transcardially
with ice-cold saline, followed by ice-cold 4% paraformaldehyde in 0.1 M sodium borate, pH 9.5. The brains were removed quickly
and postfixed overnight at 4° in 4% paraformaldehyde in borate
buffer, pH 9.5, containing 10% sucrose. Cryostat microtome sections
(25 µm) were mounted onto gelatin- and
poly-L-lysine-coated glass slides, incubated for 15 min in
4% paraformaldehyde in 0.1 M phosphate-buffered saline,
washed twice in 0.1 M phosphate-buffered saline, and
treated for 30 min at 37° in 10 mg/ml proteinase K in 100 mM Tris/50 mM EDTA, pH 8, followed by 0.0025%
acetic anhydride in 0.1 M triethanolamine at room
temperature. The sections were then washed in 2× SSC (1× SSC = 0.15 M NaCl, 0.015 M Na citrate), dehydrated in
increasing concentrations of ethanol, vacuum-dried at room temperature,
and stored at
80° until use. The probe for mGluR8 mRNA was
generated using an SmaI/XhoI cDNA fragment,
encoding amino acids 1-522, subcloned into pBluescript KS. Using
linearized template DNA, 35S-labeled antisense mGluR8 cRNA
probe was transcribed, heated to 65° for 5 min, and diluted to
107 cpm/ml in hybridization buffer (66% formamide, 260 mM NaCl, 1.3× Denhardt's solution, 13 mM
Tris, 1.3 mM EDTA, 13% dextran sulfate). The hybridization
mixture was applied to the sections, covered with siliconized glass
coverslips, and sealed using DPX mountant. After incubation at 58°
for 20-24 hr, the slides were soaked in 4× SSC to remove coverslips
and then rinsed in 4× SSC (four times for 5 min each) before
ribonuclease A treatment (20 mg/ml for 30 min at 37°). The slides
were then rinsed in decreasing concentrations of SSC containing 1 mM dithiothreitol to a final stringency of 0.1× SSC/1
mM dithiothreitol for 30 min at 65°. After dehydrating the sections in increasing concentrations of ethanol, they were vacuum-dried and exposed to DuPont Cronex-4 X-ray film for 7 days (DuPont-New England Nuclear, Boston, MA). The film was then scanned by
with an eight-bit Nikon LS3500 scanner, and the images were processed
using Adobe Photoshop. Anatomical sites were identified using the
Brain Maps atlas (15).
Functional expression of mGluR8. mGluR8 was functionally expressed in X. laevis oocytes by coexpression with GIRKs. cRNA transcripts encoding mGluR8, Kir3.1, and Kir3.4 were prepared by standard in vitro transcription reactions. Oocytes were harvested from anesthetized X. laevis (Xenopus One, Ann Arbor, MI) and enzymatically defolliculated as previously described (16). Stage V-VI oocytes were injected with 50-100 ng of a cRNA mixture containing mGluR8, Kir3.1, and Kir3.4 and then maintained at 18° in ND96 (96 mM NaCl, 2 mM KCl, 1.8 mM CaCl2, 1 mM MgCl2, and 5 mM HEPES, pH 7.5, mOsM 214) supplemented with 2.5 mM Na pyruvate, 0.5 mM theophylline (Sigma), and 50 µg/ml gentamicin (GIBCO, Grand Island, NY). For the PTX experiments, oocytes were incubated in 500 ng/ml PTX in ND96 for 48 hr before recording.
Electrophysiology.
Electrophysiological recordings were
performed 24-72 hr after injection. Patch pipettes with tip diameters
of
1-2 µm were used as electrodes and filled with 3 M
KCl. Oocytes were voltage-clamped at
80 mV in two-electrode
voltage-clamp mode (Axoclamp 2A, Axon Instruments, Burlingame, CA).
Currents were acquired at 1.6 Hz with MacLab 3.3 (AD Instruments,
Milford, MA). The oocytes were placed in a 2-ml chamber and bathed
continuously in ND96 at
3.5 ml/min. Solutions were changed using a
solenoid valve controller with an exchange time of 15-30 sec. Oocytes
were initially bathed in ND96 and then switched to a high potassium
solution (2 mM NaCl, 96 mM KCl, 1.8 mM CaCl2, 1 mM MgCl2,
10 mM HEPES, pH 7.5-7.6, mOsM 214). Agonists
(diluted in high potassium solution) were applied when the basal
potassium current (in high potassium solution) had reached equilibrium.
The high potassium solution current was subtracted from the total
current to obtain the agonist-induced current. Current amplitudes were
measured off-line and analyzed using Student's t test when
appropriate. Mean current amplitudes were normalized to the amplitude
evoked by the maximal concentration of agonist and are expressed as
mean ± standard error. A value of p < 0.05 was
considered significant. Agonist dose-response curves were fitted using
a least-squares algorithm to the Hill equation: I = Imax{1
1/[1 + ([A]/EC50)n]}, where
Imax is maximum response amplitude, [A] is agonist
concentration, EC50 is half-maximal concentration of
agonist, and n is the Hill coefficient. Antagonist
dose-inhibition curves were fitted to the equation: I = Imax{1/[1 + ([A]/IC50)]}, where
Imax is the response amplitude in the absence of
antagonist, [A] is antagonist concentration, and IC50 is
half-maximal concentration of antagonist.
| |
Results |
|---|
|
|
|---|
Sequence and expression of rat mGluR8. The rat mGluR8 cDNA sequence contains an open reading frame of 2724 bp and an initiation codon consensus sequence surrounding the presumed initiator methionine. The cDNA sequence predicts a protein of 908 amino acids with an estimated molecular mass of 101,866 Da (Fig. 1A). Rat mGluR8 has 98.6% identity with the mouse homologue with the differences depicted in Fig. 1A. Hydrophobicity analysis predicts a signal peptide sequence at the amino terminus of the receptor and seven transmembrane domains within the receptor, characteristic of G protein-coupled receptors. Characteristic of mGluRs, mGluR8 has a large amino-terminal domain (583 amino acids) and a prominent second intracellular loop, a domain of mGluRs involved in G protein coupling (17). There are five putative N-glycosylation sites in the amino terminus and three putative serine/threonine phosphorylation sites in intracellular domains. Amino acid sequence comparison of mGluR8 to other mGluRs reveals that it shares the most identity to the group III receptors (mGluR4, 75.0%; mGluR6, 69.8%; mGluR7, 74.5%) and less identity to the group I and II receptors (mGluR1, 42.9%; mGluR2, 44.5%; mGluR3, 47.2%; mGluR5, 42.4%). It also shares 29.1% identity with the bovine parathyroid calcium binding protein and 28.5% identity with the human calcium binding protein (18).
|
Distribution of mGluR8 RNA. In situ hybridization studies show that rat mGluR8 mRNA has a highly restricted expression pattern compared with that of mGluR4 and mGluR7 (21, 22). The most prominent expression was detected in the olfactory bulb, piriform cortex, pontine gray, and lateral reticular nucleus of the thalamus (Fig. 2). Lower levels of expression were also detected in the cerebral cortex, hippocampus, cerebellum, and mammillary body. In the accessory olfactory bulb, the granule cell layer had a more intense signal than the mitral cell layer. However, in the main olfactory bulb, the mitral cell layer had a more intense signal, although there was also abundant expression in the granule cell layer (Fig. 2B). Pyramidal cells of the piriform cortex also showed high levels of expression, whereas the olfactory tubercle was virtually lacking mGluR8 mRNA (Fig. 2C). The septum and layers V/VI of the isocortex expressed lower levels of mRNA, as well as the hippocampus. The mammillary body also expressed low levels of mRNA, which was in contrast to the abundant expression detected in the mouse homologue (2). However, the rat homologue showed prominent expression in the pontine gray (Fig. 2D) and the lateral reticular nucleus of the thalamus (Fig. 2E).
|
Pharmacological profile of mGluR8.
In X. laevis
oocytes coexpressing mGluR8 and GIRK, glutamate, L-AP4, L-CCG-1, and
ACPD all evoked inward potassium currents in high potassium solution.
Currents evoked by L-CCG-1 were dose dependent, as shown for one oocyte
(Fig. 3A). The concentration-response curves were
plotted by normalizing the current amplitudes to the response evoked by
a saturating agonist concentration for each oocyte (Fig. 3B). The
pharmacological profile for mGluR8 was L-CCG-1
L-AP4 > glutamate
ACPD with EC50 values of 0.63, 0.67, 2.5, and 47 µM, respectively. ACPD was a partial agonist
because saturating concentrations of glutamate evoked currents that
were 2-fold larger than those evoked by saturating concentrations of
ACPD (six oocytes, data not shown). The Hill coefficients for the high
affinity ligands were much lower (L-CCG-1 = 0.6;, L-AP4 = 0.9) than for the two lower affinity ligands (ACPD = 1.7;
glutamate = 1.9).
|
|
| |
Discussion |
|---|
|
|
|---|
We isolated and expressed the cDNA encoding rat mGluR8 that shows a restricted expression pattern in the adult rat brain. mGluR8 is a group III mGluR based on amino acid homology and activation by L-AP4. However, the pharmacology of mGluR8 was distinct. MCPG, considered to a group I/II antagonist, inhibited mGluR8. Likewise, mGluR8 was activated by low concentrations of L-CCG-1, suggesting similarities in the binding domains of group II and III mGluRs. Thus, cellular responses with mixed group II/III behavior may in some cases reflect activation of mGluR8 rather than the additive effects of two mGluRs.
The pharmacological profile of mGluR8 does not fit the structural classification of receptor subtypes. In general, the reported selectivity of newer generation mGluR ligands has been consistent with the group classification that was based on structural homology. The similar high affinity of L-CCG-1 for mGluR8 as well as the group II receptors is unusual in that regard, perhaps reflecting the somewhat higher homology of group II and III receptors in the gene family (2). In addition, one recent report found that low concentrations of L-CCG-I can activate another group III receptor, mGluR4a (27). The inhibition of mGluR2 by MAP4, previously regarded as group III specific, is also consistent with similarities in the pharmacological properties between groups II and III mGluRs (10).
Such pharmacological overlap is not entirely surprising because the ligand binding pocket of mGluRs in the extracellular amino terminus is among the most conserved domains, being homologous to bacterial periplasmic binding proteins (28). For example, Ser165 and Thr188, which are critical to glutamate binding in mGluR1, are conserved in all mGluRs. The "universal" action of glutamate at ionotropic and metabotropic receptors is presumably due to its molecular flexibility and the length of its carbon backbone. In contrast, the conformationally restricted analogs ACPD and DCG-IV seem to be selective for all mGluRs and group II mGluRs, respectively. However, the degree of conformational restriction is not sufficient to account for the selectivity of various mGluR agonists. For example, the flexible analog of glutamate, L-AP4, is selective for group III receptors, presumably based on the bioisosteric replacement of a carboxyl group by a phosphono group. MCPG and MAP4 also show limited selectivity between group I and III receptors in that they antagonize both mGluR2 (10) as well as mGluR8. Thus, more-selective drugs will be necessary to distinguish between group II and group III receptors.The features of mGluR8 coupling to GIRK in oocytes.
We used
the ability of mGluRs to couple to GIRK as a convenient assay to test
the pharmacological properties of mGluR8. The coupling of mGluR8 to
GIRK was PTX sensitive, which is consistent with other group II/III
mGluRs. Likewise, mGluR8 did not activate phospholipase C, the effector
for group I receptors. It is not yet clear whether GIRK activation by
mGluRs occurs in neurons (12). However, the GIRK assay revealed some
interesting differences between agonists that activated mGluR8. In
particular, the Hill slope of the mGluR/GIRK dose-response curves was
strikingly different for the high affinity agonists (L-CCG-1, 0.6;
L-AP4, 0.9) than for the lower affinity agonists (ACPD, 1.7; glutamate,
1.9). Hill coefficients reflect multiple steps from G protein-coupled
receptor activation to the effector response. In our experiments, the
final step is activation of GIRK by G
subunits (29). Receptors
when coupled to G proteins often show a higher affinity for agonists, accounting for the GTP dependence of agonist binding for many G
protein-coupled receptors. Thus, binding of agonists to the high and
low affinity states of a receptor can create dose-responses curves with
a shallow slope (30). This effect is more apparent for agonists with
higher affinities, which is consistent with the shallower slopes for
L-CCG-I and L-AP4. The supralinearity of the Hill coefficients for
glutamate and ACPD also implies cooperativity at some stage in the
pathway other than receptor activation. Because there presumably is
only one agonist binding site per mGluR (28), other steps in the
cascade must be responsible for the supralinear Hill coefficients. This
step could be due to G
subunit activation of GIRK channels
because Hill coefficients for this interaction range from 1.5 to 3 (31,
32). Similar to our results, GABAB receptor responses in
hippocampal neurons also show a supralinear relationship for activation
of G protein-coupled potassium conductances (Hill coefficient = 1.7; Ref. 33).
Functional roles for mGluR8. The distribution patterns of mGluRs vary widely, with some receptors showing extremely restricted patterns (e.g., mGluR6), whereas others are very broadly expressed (e.g., mGluR1). The tissue distribution of mGluR8 mRNA was most prominent in three regions of the central nervous system. The pontine gray that projects to the cerebellum shows high levels of mGluR8 mRNA, whereas mGluR4 is highly expressed in cerebellar granule cells (21). This distribution suggests that group III receptors may influence motor control. The lateral reticular nucleus of the thalamus also shows prominent mGluR8 RNA expression. The GABAergic input of lateral reticular nucleus neurons onto thalamic relay neurons is critical in the synchronization of thalamocortical circuits in sleep and in primary generalized seizures. ACPD can postsynaptically enhance excitability of thalamic relay neurons, presumably via a group I mGluR. However, blockade of GIRK-mediated GABAB responses in relay neurons has been shown to abolish these synchronized oscillations (34). Thus, it will be interesting to examine whether mGluR8 modifies the activity of this circuit via GIRK or other effectors.
In the olfactory bulb, mGluR8 mRNA is prominent in both the mitral and granule cell layer, regions that also express other group III receptors. For example, L-AP4 inhibits transmitter release at mitral cells axons (35, 36). This effect initially seemed to be due to mGluR7, the first L-AP4-sensitive mGluR to be identified in mitral cells (9, 11). The seemingly redundant colocalization of mGluR7 and mGluR8 conceivably could be explained by selective targeting. However, subcellular targeting is not the complete explanation because mitral cell nerve terminals also seem to contain both mGluR7 and mGluR8 (38).3 However, these two group III receptors could serve complementary functions at nerve terminals. mGluR7 requires high levels of glutamate for activation (EC50
1 mM)
compared with mGluR8 (EC50
2.5 µM). On
interneurons expressing mGluR1a, hippocampal presynaptic active zones
have a
10-fold higher level of mGluR7 than other terminals (39).
Thus, at least at these synapses, mGluR7 receptors must be transiently
exposed to millimolar levels of glutamate in the cleft (40), suggesting
a role for mGluR7 in homosynaptic modulation. Because mGluR8 is also
located presynaptically (38), its higher sensitivity may allow
activation by spillover of glutamate onto neighboring synapses, thus
providing a mechanism for heterosynaptic modulation.
| |
Footnotes |
|---|
Received July 31, 1996; Accepted September 25, 1996
1 Current affiliation: Department of Pharmacology, Emory University Atlanta, GA 30322.
2 GenBank accession no. U63288.
3 J. M. Kinzie, M. M. Shinohara, A. van den Pol, G. L. Westbrook, and T. P. Segerson. Immunolocalization of metabotropic glutamate receptor 7 in the adult rat olfactory system, submitted for publication.
This work was supported by National Institutes of Health Fellowships F32-NS09200 (J.A.S.), F30-MH10314 (J.M.K.), R01-DC01783 (T.P.S.), and R01-NS26494 (G.L.W.). We thank Weibin Zhang for harvesting the oocytes.
Send reprint requests to: Dr. Gary L. Westbrook, Vollum Institute, L474, Oregon Health Sciences University, 3181 S.W. Sam Jackson Park Road, Portland, OR 97201. E-mail: westbroo{at}ohsu.edu
| |
Abbreviations |
|---|
mGluR, metabotropic glutamate receptor;
GIRK, G protein-coupled inwardly rectifying potassium channel;
L-AP4, L-2-amino-4-phosphonobutyric acid;
L-CCG-1, [2(S),1
(S),2
(S)]-2-(carboxycyclopropyl)glycine;
ACPD, [1(S),3(R)]-1-aminocyclopentane-1,3-dicarboxylic
acid;
MCPG, (R,S)-
-methyl-4-carboxyphenylglycine;
MAP4,
-methyl-amino-phosphonobutyrate;
DCG-IV, [2(S),1
(R),2
(R),3
(R)]-2-(2,3-dicarboxycyclopropyl)glycine;
DHPG, 3,5-dihydroxyphenylglycine;
GABA,
-aminobutyric acid;
SSC, standard saline citrate;
PTX, pertussis toxin;
HEPES, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid.
| |
References |
|---|
|
|
|---|
| 1. | Pin, J.-P. and J. Bockaert. Get receptive to metabotropic glutamate receptors. Curr. Opin. Neurobiol. 5:342-349 (1995)[Medline]. |
| 2. | Duvoisin, R. M., C. Zhang, and K. Ramonell. A novel metabotropic glutamate receptor expressed in the retina and olfactory bulb. J. Neurosci. 15:3075-3083 (1995)[Abstract]. |
| 3. | Hayashi, Y., A. Momiyama, T. Takahashi, H. Ohishi, R. Ogawa-Meguro, R. Shigemoto, N. Mizuno, and S. Nakanishi. Role of a metabotropic glutamate receptor in synaptic modulation in the accessory olfactory bulb. Nature (Lond.) 366:687-690 (1993)[Medline]. |
| 4. | Nomura, A., R. Shigemoto, Y. Nakamura, N. Okamoto, N. Mizuno, and S. Nakanishi. Developmentally regulated postsynaptic localization of a metabotropic glutamate receptor in rat rod bipolar cells. Cell 77:361-369 (1994)[Medline]. |
| 5. | Jane, D. E., K. Pittaway, D. C. Sunter, N. K. Thomas, and J. C. Watkins. New phenylglycine derivatives with potent and selective antagonist activity at presynaptic glutamate receptors in neonatal rat spinal cord. Neuropharmacology 34:851-856 (1995)[Medline]. |
| 6. | Kemp, M., P. Roberts, P. Pook, D. Jane, A. Jones, P. Jones, D. Sunter, P. Udvarhelyi, and J. Watkins. Antagonism of presynaptically mediated depressant responses and cyclic AMP-coupled metabotropic glutamate receptors. Eur. J. Pharm. 266:187-192 (1994)[Medline]. |
| 7. | Manzoni, O. J., P. E. Castillo, and R. A. Nicoll. Pharmacology of metabotropic glutamate receptors at the mossy fiber synapses of the guinea pig hippocampus. Neuropharmacology 34:965-971 (1995)[Medline]. |
| 8. | Hayashi, Y., N. Sekiyama, S. Nakanishi, D. E. Jane, D. C. Sunter, E. F. Birse, P. M. Udvarhelyi, and J. C. Watkins. Analysis of agonist and antagonist activities of phenylglycine derivatives for different cloned metabotropic glutamate receptor subtypes. J. Neurosci. 14:3370-3377 (1994)[Abstract]. |
| 9. | Saugstad, J. A., J. M. Kinzie, E. R. Mulvihill, T. P. Segerson, and G. L. Westbrook. Cloning and expression of a new member of the L-2-amino-4-phosphonobutyric acid- sensitive class of metabotropic glutamate receptors. Mol. Pharmacol. 45:367-372 (1994)[Abstract]. |
| 10. |
Gomeza, J.,
S. Mary,
I. Brabet,
M.-L. Parmentier,
S. Restituito,
J. Bockaert, and
J.-P. Pin.
Coupling of mGluR2 and mGluR4 to G 15, G 16, and chimeric G q/i proteins: characterization of new antagonists.
Mol. Pharmacol.
50:923-930 (1996)[Abstract].
|
| 11. |
Okamoto, N.,
S. Hori,
C. Akazawa,
Y. Hayashi,
R. Shigemoto,
N. Mizuno, and
S. Nakanishi.
Molecular characterization of a new metabotropic glutamate receptor mGluR7 coupled to inhibitory cyclic AMP signal transduction.
J. Biol. Chem.
269:1231-1236 (1994) |
| 12. |
Saugstad, J. A.,
T. P. Segerson, and
G. L. Westbrook.
Metabotropic glutamate receptors activate G protein-coupled inwardly rectifying potassium channels in Xenopus oocytes.
J. Neurosci.
16:5979-5985 (1996) |
| 13. | Hayashi, Y., Y. Tanabe, I. Aramori, M. Masu, K. Shimamoto, Y. Ohfune, and S. Nakanishi. Agonist analysis of 2-(carboxycyclopropyl)glycine isomers for cloned metabotropic glutamate receptor subtypes expressed in Chinese hamster ovary cells. Br. J. Pharmacol. 107:539-545 (1992)[Medline]. |
| 14. |
Abe, T.,
H. Sugihara, and
H. Nawa.
R.Shigemoto, N. Mizuno, and S. Nakanishi. Molecular characterization of a novel metabotropic glutamate receptor mGluR5 coupled to inositol phosphate/Ca2+ signal transduction.
J. Biol. Chem.
267:13361-13368 (1992) |
| 15. | Swanson, L. W. Brain Maps: Structure of the Rat Brain. Elsevier Science Publishers B. V., Amsterdam (1992). |
| 16. | Saugstad, J. A., T. P. Segerson, and G. L. Westbrook. L-2-Amino-3-phosphonopropionic acid competitively antagonizes metabotropic glutamate receptors 1a and 5 in Xenopus oocytes. Eur. J. Pharm. 289:395-397 (1995)[Medline]. |
| 17. | Pin, J.-P., C. Joly, S. F. Heinemann, and J. Bockaert. Domains involved in the specificity of G protein activation in phospholipase C-coupled metabotropic glutamate receptors. EMBO J. 13:342-348 (1994)[Medline]. |
| 18. | Hebert, S. C. and E. M. Brown. The extracellular calcium receptor. Curr. Opin. Cell Biol. 7:484-492 (1995)[Medline]. |
| 19. | Kubo, Y., E. Reuveny, P. A. Slesinger, Y. N. Jan, and L. Y. Jan. Primary structure and functional expression of a rat G-protein-coupled muscarinic potassium channel. Nature (Lond.) 364:802-806 (1993)[Medline]. |
| 20. | Krapivinsky, G., E. A. Gordon, K. Wickman, B. Velimirovic, L. Krapivinsky, and D. E. Clapham. The G-protein-gated atrial K+ channel IkAch is a heteromultimer of two inwardly rectifying K+-channel proteins. Nature (Lond.) 374:135-141 (1995)[Medline]. |
| 21. | Tanabe, Y., A. Nomura, M. Masu, R. Shigemoto, N. Mizuno, and S. Nakanishi. Signal transduction, pharmacological properties, and expression patterns of two rat metabotropic glutamate receptors, mGluR3 and mGluR4. J. Neurosci. 13:1372-1378 (1993)[Abstract]. |
| 22. | Kinzie, J. M., J. A. Saugstad, G. L. Westbrook, and T. P. Segerson. Distribution of metabotropic glutamate receptor 7 mRNA in the developing and adult rat brain. Neuroscience 69:167-176 (1995)[Medline]. |
| 23. | Ishida, M., T. Saitoh, K. Shimamoto, Y. Ohfune, and H. Shinozaki. A novel metabotropic glutamate receptor agonist: marked depression of monosynaptic excitation in the newborn rat. Br. J. Pharmacol. 109:1169-1177 (1993)[Medline]. |
| 24. | Jane, D. E., P. L. Jones, P. C. Pook, H. W. Tse, and J. C. Watkins. Actions of two new sub-type selective metabotropic glutamate receptor antagonists in the neonatal rat spinal cord. Br. J. Pharmacol. 112:809-816 (1994)[Medline]. |
| 25. |
Salt, T. E. and
S. A. Eaton.
Distinct presynaptic metabotropic receptors for L-AP4 and CCG1 on GABAergic terminals: pharmacological evidence using novel -Methyl derivative mGluR antagonists, MAP4 and MCCG, in the rat thalamus in vivo.
Neuroscience
65:5-13 (1995)[Medline].
|
| 26. | Bushell, T. J., D. E. Jane, J. C. Watkins, C. H. Davies, J. Garthwaite, and G. L. Collingridge. Antagonism of the synaptic depressant actions of L-AP4 in the lateral perforant path by MAP4. Neuropharmacology 34:239-241 (1995)[Medline]. |
| 27. | Eriksen, L. and C. Thomsen. [3H]-L-2-amino-4-phosphonobutyrate labels a metabotropic receptor, mGluR4a. Br. J. Pharm. 116:3279-3287 (1996)[Medline]. |
| 28. | O'Hara, P. J., P. O. Sheppard, H. Thøgersen, D. Venezia, B. A. Haldeman, V. McGrane, K. M. Houamed, C. Thomsen, T. L. Gilbert, and E. R. Mulvihill. The ligand-binding domain in metabotropic glutamate receptors is related to bacterial periplasmic binding proteins. Neuron 11:41-52 (1993)[Medline]. |
| 29. |
Reuveny, E.
Slesinger, P. A. Inglese, J. Morales, J. M. Iñiguez-Lluhi, J. A. Lefkowitz, R. J. Bourne, H. R. Jan, and L. Y. Jan. Activation of the cloned muscarinic potassium channel by G protein ![]() subunits.
Nature (Lond.)
370:143-146 (1994)[Medline].
|
| 30. | Waelbroeck, M., P. Robberecht, P. Chatelain, and J. Christophe. Rat cardiac muscarinic receptors: effects of guanine nucleotides on high- and low-affinity binding sites. Mol. Pharmacol. 21:581-588 (1981)[Abstract]. |
| 31. |
Ito, H.,
R. T. Tung,
T. Sugimoto,
I. Kobayashi,
K. Takasashi,
T. Katada,
M. Ui, and
Y. Kurachi.
On the mechanism of G protein ![]() subunit activation of the muscarinic K+ channel in guinea pig atrial cell membrane.
J. Gen. Physiol.
99:961-983 (1992) |
| 32. |
Krapivinsky, G.,
L. Krapivinsky,
K. Wickman, and
D. E. Clapham.
G![]() binds directly to the G protein-gated K channel, IkAch.
J. Biol. Chem.
270:29059-29062 (1995) |
| 33. |
Sodickson, D. L. and
B. P. Bean.
GABAB receptor-activated inwardly-rectifying potassium current in dissociated hippocampal CA3 neurons.
J. Neurosci.
16:6374-6385 (1996) |
| 34. |
von Krosigk, M.,
T. Bal, and
D. A. McCormick.
Cellular mechanisms of a synchronized oscillation in the thalamus.
Science (Washington D. C.)
261:361-364 (1993) |
| 35. | Anson, J. and G. G. S. Collins. Possible presynaptic actions of 2-amino-4-phosphonobutyrate in rat olfactory cortex. Br. J. Pharmacol. 91:753-761 (1987)[Medline]. |
| 36. | Trombley, P. Q. and G. L. Westbrook. L-AP4 inhibits calcium currents and synaptic transmission via a G protein-coupled glutamate receptor. J. Neurosci. 12:2043-2050 (1992)[Abstract]. |
| 37. | Deleted in proof.Deleted in proof. |
| 38. | Kinoshita, A., H. Ohishi, A. Neki, S. Nomura, R. Shigemoto, M. Takada, S. Nakanishi, and N. Mizuno. Presynaptic localization of a metabotropic glutamate receptor, mGluR8, in the rhinencephalic areas: a light and electron microscope study in the rat. Neurosci. Lett. 207:61-64 (1996)[Medline]. |
| 39. | Shigemoto, R., A. Kulik, J. D. B. Roberts, H. Ohishi, Z. Nusser, T. Kaneko, and P. Somogyi. Target-cell-specific concentration of a metabotropic glutamate receptor in the presynaptic active zone. Nature (Lond.) 381:523-525 (1996)[Medline]. |
| 40. |
Clements, J. D.,
R. A. J. Lester,
G. Tong,
C. E. Jahr, and
G. L. Westbrook.
The time course of glutamate in the synaptic cleft.
Science (Washington D. C.)
258:1498-1501 (1992) |
This article has been cited by other articles:
![]() |
C. M. Niswender, K. A. Johnson, Q. Luo, J. E. Ayala, C. Kim, P. J. Conn, and C. D. Weaver A Novel Assay of Gi/o-Linked G Protein-Coupled Receptor Coupling to Potassium Channels Provides New Insights into the Pharmacology of the Group III Metabotropic Glutamate Receptors Mol. Pharmacol., April 1, 2008; 73(4): 1213 - 1224. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Heinbockel, N. Laaris, and M. Ennis Metabotropic Glutamate Receptors in the Main Olfactory Bulb Drive Granule Cell-Mediated Inhibition J Neurophysiol, January 1, 2007; 97(1): 858 - 870. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Li and V. Neugebauer Differential Changes of Group II and Group III mGluR Function in Central Amygdala Neurons in a Model of Arthritic Pain J Neurophysiol, October 1, 2006; 96(4): 1803 - 1815. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Tang, O. E. Far, H. Betz, and A. Scheschonka Pias1 Interaction and Sumoylation of Metabotropic Glutamate Receptor 8 J. Biol. Chem., November 18, 2005; 280(46): 38153 - 38159. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Ferraguti, T. Klausberger, P. Cobden, A. Baude, J. D. B. Roberts, P. Szucs, A. Kinoshita, R. Shigemoto, P. Somogyi, and Y. Dalezios Metabotropic Glutamate Receptor 8-Expressing Nerve Terminals Target Subsets of GABAergic Neurons in the Hippocampus J. Neurosci., November 9, 2005; 25(45): 10520 - 10536. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Renden, H. Taschenberger, N. Puente, D. A. Rusakov, R. Duvoisin, L.-Y. Wang, K. P. Lehre, and H. von Gersdorff Glutamate Transporter Studies Reveal the Pruning of Metabotropic Glutamate Receptors and Absence of AMPA Receptor Desensitization at Mature Calyx of Held Synapses J. Neurosci., September 14, 2005; 25(37): 8482 - 8497. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Guo and S. R. Ikeda Coupling of Metabotropic Glutamate Receptor 8 to N-Type Ca2+ Channels in Rat Sympathetic Neurons Mol. Pharmacol., June 1, 2005; 67(6): 1840 - 1851. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Skov, S. Nedergaard, and M. Andreasen New Type of Synaptically Mediated Epileptiform Activity Independent of Known Glutamate and GABA Receptors J Neurophysiol, April 1, 2005; 93(4): 1845 - 1856. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Koulen, J. Liu, E. Nixon, and C. Madry Interaction between mGluR8 and Calcium Channels in Photoreceptors Is Sensitive to Pertussis Toxin and Occurs Via G Protein {beta}{gamma} Subunit Signaling Invest. Ophthalmol. Vis. Sci., January 1, 2005; 46(1): 287 - 291. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Heinbockel, P. Heyward, F. Conquet, and M. Ennis Regulation of Main Olfactory Bulb Mitral Cell Excitability by Metabotropic Glutamate Receptor mGluR1 J Neurophysiol, November 1, 2004; 92(5): 3085 - 3096. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Uehara, A. Muroyama, N. Echigo, R. Morimoto, M. Otsuka, S. Yatsushiro, and Y. Moriyama Metabotropic Glutamate Receptor Type 4 Is Involved in Autoinhibitory Cascade for Glucagon Secretion by {alpha}-Cells of Islet of Langerhans Diabetes, April 1, 2004; 53(4): 998 - 1006. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Pisani, P. Bonsi, M. V. Catania, R. Giuffrida, M. Morari, M. Marti, D. Centonze, G. Bernardi, A. E. Kingston, and P. Calabresi Metabotropic Glutamate 2 Receptors Modulate Synaptic Inputs and Calcium Signals in Striatal Cholinergic Interneurons J. Neurosci., July 15, 2002; 22(14): 6176 - 6185. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Koulen and J. H. Brandstatter Pre- and Postsynaptic Sites of Action of mGluR8a in the Mammalian Retina Invest. Ophthalmol. Vis. Sci., June 1, 2002; 43(6): 1933 - 1940. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Millan, R. Lujan, R. Shigemoto, and J. Sanchez-Prieto The Inhibition of Glutamate Release by Metabotropic Glutamate Receptor 7 Affects Both [Ca2+]c and cAMP. EVIDENCE FOR A STRONG REDUCTION OF Ca2+ ENTRY IN SINGLE NERVE TERMINALS J. Biol. Chem., April 12, 2002; 277(16): 14092 - 14101. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. D. Schoepp Unveiling the Functions of Presynaptic Metabotropic Glutamate Receptors in the Central Nervous System J. Pharmacol. Exp. Ther., October 1, 2001; 299(1): 12 - 20. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. J. Hoang and M. Hay Expression of metabotropic glutamate receptors in nodose ganglia and the nucleus of the solitary tract Am J Physiol Heart Circ Physiol, July 1, 2001; 281(1): H457 - H462. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. I. Evans, R. S. G. Jones, and G. Woodhall Differential Actions of PKA and PKC in the Regulation of Glutamate Release by Group III mGluRs in the Entorhinal Cortex J Neurophysiol, February 1, 2001; 85(2): 571 - 579. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Bruno, G. Battaglia, I. Ksiazek, H. van der Putten, M. V. Catania, R. Giuffrida, S. Lukic, T. Leonhardt, W. Inderbitzin, F. Gasparini, et al. Selective Activation of mGlu4 Metabotropic Glutamate Receptors Is Protective against Excitotoxic Neuronal Death J. Neurosci., September 1, 2000; 20(17): 6413 - 6420. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. C. Snead III, P. K. Banerjee, M. Burnham, and D. Hampson Modulation of Absence Seizures by the GABAA Receptor: A Critical Role for Metabotropic Glutamate Receptor 4 (mGluR4) J. Neurosci., August 15, 2000; 20(16): 6218 - 6224. [Abstract] [Full Text] [PDF] |
||||